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During the past two decades, considerable research has been devoted to radionuclide
therapy using radiolabeled monoclonal antibodies and receptor binding agents. Conven-
tional radioimmunotherapy (RIT) is now an established and important tool in the treatment
of hematologic malignancies such as Non-Hodgkin lymphoma. For solid malignancies, the
efficacy of RIT has not been as successful due to lower radiosensitivity, difficult penetration
of the antibody into the tumor, and potential excessive radiation to normal tissues. Inno-
vative approaches have been developed in order to enhance tumor absorbed dose while
limiting toxicity to overcome the different limitations due to the tumor and host character-
istics. Pretargeting techniques (pRIT) are a promising approach that consists of decoupling
the delivery of a tumor monoclonal antibody (mAb) from the delivery of the radionuclide.
This results in a much higher tumor-to-normal tissue ratio and is favorable for therapy as
well and imaging.This includes various strategies based on avidin/streptavidin-biotin, DNA-
complementary DNA, and bispecific antibody-hapten bindings. pRIT continuously evolves
with the investigation of new molecular constructs and the development of radiochem-
istry. Pharmacokinetics improve dosimetry depending on the radionuclides used (alpha,
beta, and Auger emitters) with prediction of tumor response and host toxicities. New
constructs such as the Dock and Lock technology allow production of a variety of mABs
directed against tumor-associated antigens. Survival benefit has already been shown in
medullary thyroid carcinoma. Improvement in delivery of radioactivity to tumors with
these pretargeting procedures associated with reduced hematologic toxicity will become
the next generation of RIT. The following review addresses actual technical and clinical
considerations and future development of pRIT.
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INTRODUCTION
Conventional radioimmunotherapy (RIT) using an intravenously
injected directly radiolabeled antibody has been extensively tested
in preclinical and clinical studies. Its efficacy has been clearly doc-
umented in the most favorable clinical setting of disseminated
small-size tumors especially those that are rapidly accessible to
the injected antibody, such as bone marrow (Morschhauser et al.,
2008). This efficacy has been limited in the situation of large
tumor burden except for non-Hodgkin Lymphoma which is highly
radiosensitive and thus needs a relatively small absorbed dose for
an objective response. With these large tumors there is a consid-
erable distance before the antibody molecule comes into contact
with cancer cells. Some physiological barriers prevent the rapid
diffusion of an antibody into the tumor. After reaching it the anti-
body molecule first encounters the antigen present at the surface
of tumor cells in the perivascular space. A high binding affinity
of the antibody can impede it from migrating deeply into the
tumor whereas a low binding affinity allows a deeper penetration
into the tumor (Sharkey and Goldenberg, 2005). After injection it
takes 2–3 days before a maximum level of antibody concentration
is reached within the tumor. Finally, in general only a very small
fraction of the injected activity will localize to the tumor, which
explains the modest response rate that is usually observed.
As optimal tumor targeting requires a high tumor uptake and
a low retention of radioactivity in normal tissues, especially in the
blood, the situation is not favorable for large tumors over 3–4 cm
in diameter. One way to improve this situation is to hasten anti-
body blood clearance by reducing the molecular size. Molecular
engineering has allowed production of antibody forms with var-
ied valencies and molecular sizes. One problem with smaller sized
antibodies or antibody fragments is a faster clearance from the
blood which is favorable for normal tissue toxicity, but also results
in a low tumor uptake and retention with low tumor absorbed
dose and no therapeutic efficacy.
Thus it appears that for unique or multiple macroscopic tumor
targets larger than 3–4 cm in diameter, RIT with directly labeled
antibodies cannot be therapeutically efficient. At best it can bring
a useful contribution when used in combination with chemother-
apy. This is why there is a critical need for innovative approaches to
allow enhanced tumor absorbed doses whilst limiting hematologic
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toxicity. Pretargeting techniques can at least partially solve this
problem.
PRETARGETED RIT TECHNIQUES
The principle of pretargeted RIT consists of decoupling the deliv-
ery of a tumor specific antibody from the delivery of the radionu-
clide. In the first step a large saturating dose of the unlabeled
antibody is injected and distributes throughout the body. The anti-
body molecule slowly binds to the tumor cells while clearing from
other tissues. In the second step, at a later time of 2–4 days, when
the concentration of the antibody in the tumor is at its peak and
much higher than in normal organs,a radioactive small molecule is
injected and rapidly reaches the tumor where it specifically binds
to the pre-localized antibody. By comparison to the method of
directly labeled antibody it results a much higher tumor-to-normal
tissue ratio which is favorable for therapy.
METHODS BASED ON AVIDIN/STREPTAVIDIN-BIOTIN BINDING
Several pretargeting methods have been developed including two
in clinical studies: one of them was based on the four binding sites
and the very high affinity (10−15 M) of avidin for biotin (Hna-
towich et al., 1987). In a first approach streptavidin is conjugated to
an antibody molecule and intravenously injected. A few days later,
radiolabeled biotin is injected and rapidly binds to tumor-localized
streptavidin. Due to the large size of the streptavidin-antibody
conjugate that results in a long residence time in the blood it is
necessary to remove excess streptavidin-antibody conjugate from
the blood using a clearing agent before injection of the radiola-
beled biotin. In a second approach, biotin is conjugated to the
antibody molecule. One or two days later, avidin which is glyco-
sylated and rapidly cleared by the liver, is injected and removes
biotin-antibody conjugate from the blood. Thirty minutes later
streptavidin, which is not glycosylated and thus not cleared by
the liver, is injected and after reaching the tumor binds strongly
to the pre-localized biotin-antibody conjugate resulting in a high
tumor-to-normal tissue ratio similar to the first approach.
Several antibodies have been conjugated with streptavidin and
clinically tested (Knox et al., 2000; Shen et al., 2005). Interest-
ingly, a 10-fold improvement of tumor-to-normal tissue ratios was
observed with regard to the same directly radiolabeled antibod-
ies confirming the interest of this approach. Using the three-step
method with a biotin-antibody conjugate followed by avidin and
streptavidin and then radiolabeled biotin, several clinical trials
have been performed in Milan, Italy in patients with high-grade
gliomas (Paganelli et al., 1998; Cremonesi et al., 1999; Grana et al.,
2002). In comparison to a directly radiolabeled antibody, the three-
step method allowed the injection of an activity of 90Y-biotin five
times higher due to a much lower blood radioactive concentra-
tion. A total of 85 patients have been treated in 2 successive phase
I and II studies. Quite interestingly, after a long follow-up life
expectancy was longer than in the control group. Survival time
was 33.5 months as compared with only 8 months for the control
group (Grana et al., 2002).
METHOD BASED ON DNA-COMPLEMENTARY DNA BINDING
The rationale for choosing this binding system is based on
the high affinity of the interaction and non-immunogenicity
of the oligonucleotides. However, the suitability of the native
phosphodiester DNA as an effector is limited by its susceptibil-
ity to nuclease hydrolysis. Morpholino oligomers (MORFs), are
synthetic DNA analogs that have been reported to be water solu-
ble, stable to nucleases, and highly specific for its complementary
MORF (Liu et al., 2002). Several preclinical studies have been per-
formed with 188Re (Liu et al., 2010) and 90Y (Liu et al., 2011) and
tended to confirm the interest of this pretargeting technique, with
high tumor-to-normal tissue ratios but no clinical study has been
implemented yet.
METHOD BASED ON BISPECIFIC ANTIBODY-HAPTEN BINDING
This alternative method initially called“Affinity Enhancement Sys-
tem (AES)” was first designed and developed in France and later
optimized in the USA. It consists of firstly injecting an unlabeled
bispecific antibody (BsmAb) made of an equimolecular amount of
a Fab’ fragment of an anti-carcinoembryonic antigen (CEA) anti-
body and a Fab’ fragment of an anti-DTPA-indium antibody. A
few days later a radiolabeled bivalent hapten that quickly binds to
the pre-localized BsmAb is injected and. In this system, the affinity
of the hapten is limited but the bivalent hapten binds avidly to the
BsmAb bound at the surface of tumor cells whereas the BsmAb-
hapten complexes can dissociate in the blood with clearance of
excess hapten through the kidneys.
The advantage of this pretargeting system with regard to
directly radiolabeled antibodies was first documented preclinically
in CEA-positive-human colorectal tumors (Gautherot et al., 1997).
Biodistribution and therapeutic efficacy with the two-step method
were compared with that of a directly labeled antibody using
iodine-125 or iodine-131. With the directly labeled antibody maxi-
mal tumor uptake was observed late at 2 days and was higher than
that of the two-step technique which showed a maximal tumor
uptake at 1 h. Meanwhile, the directly labeled antibody cleared
slowly from the blood by comparison with the radiolabeled hapten
which cleared very rapidly. As a result very high tumor-to-blood
ratios were achieved quickly with the two-step method. Conse-
quently, for therapeutic application, a higher activity of iodine-131
was injected with the two-step method (111 MBq) compared to
only 12 MBq with the directly labeled antibody, resulting in an
equivalent hematologic toxicity in both groups. Due to the much
higher injected activity with the radiolabeled hapten, therapeutic
efficacy was much better with the two-step method with a tumor
growth inhibition sustained over 150 days compared to the directly
labeled antibody which induced only a growth delay of 53 days.
The results of this preclinical study were then confirmed by
a clinical study in 11 patients with primary colorectal cancer
(Le Doussal et al., 1993). These patients were injected with 1–
10 mg of an anti-CEA/anti-DTPA BsmAb and 2–8 days later with
an 111In-labeled DTPA dimer (222 MBq). The tumor was surgi-
cally resected 1–4 days after the last injection. The biodistribution
results were compared with those obtained in six patients with sim-
ilar clinical status and injected with directly labeled 111In-labeled
anti-CEA F(ab’)2. Tumor uptake measured from resected tumors
using the two-step approach was 1.8–17.5% injected dose/kg and
not significantly lower than that found in the six patients injected
with directly labeled antibody (5.5–30.2% injected dose/kg). Inter-
estingly however, tumor-to-blood and tumor-to-liver ratios were
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significantly improved with the two-step method in comparison
with the one-step method (7.8 versus 4.2 for blood and 2.8 versus
0.8 for liver).
At this time the next consideration was what was the most
appropriate clinical setting to clearly demonstrate the superiority
of pretargeted RIT over conventional RIT with directly radiola-
beled antibody. The final choice was medullary thyroid carcinoma
(MTC) despite the low frequency of this type of cancer. Indeed
this type of cancer is known to be well-vascularized and expresses
a high density of CEA at the cell surface. Moreover, some specific
biomarkers, namely calcitonin (Ct) and CEA, allow the evolution
of the disease and the response to treatment to be monitored.
Pretargeting studies in this setting started at the beginning of the
1990s and lasted more than 15 years.
AES PRETARGETED RIT IN MEDULLARY THYROID
CARCINOMA
CONVENTIONAL TREATMENT AND PROGNOSIS OF MTC
Medullary thyroid carcinoma represents less than 10% of all thy-
roid carcinoma and occurs both as a familial and a sporadic disease
(Tubiana et al., 1968). Total thyroidectomy with lymph node dis-
section is the primary treatment. After surgery, serum Ct is not
detectable in more than 60% of patients without lymph node
involvement, versus less than 20% of patients with lymph node
spread (Machens et al., 2005; Fialkowski et al., 2008). As with other
neuroendocrine tumors, prognosis of MTC is very heterogeneous
and determination of prognostic indicators appears relevant (Byar
et al., 1979; Tisell et al., 2003; Ito et al., 2005; Machens et al., 2005;
Elisei et al., 2008; Fialkowski et al., 2008). In metastatic disease,
cytoreductive therapeutic options are limited. Targeted therapy
can be applied in progressive metastatic patients. Recently, dis-
ease stabilization has been reported with targeted therapy using
multikinase inhibitors (MKIs) in advanced or metastatic MTC,
and vandetanib has been approved in the USA (de Groot et al.,
2007; Schlumberger et al., 2009; Lam et al., 2010; Wells et al., 2010,
2012). Prognosis of metastatic MTC varies from long- to short-
term survival and highly reliable prognostic factors are needed
for early detection of high-risk patients who require treatment,
whereas low-risk patients warrant a “watch-and-wait” approach.
The identification of predictive markers of response and survival
appears very important in selecting patients most likely to ben-
efit from a systemic therapy and to avoid exposing patients who
are unlikely to respond or who have a long life expectancy from
possible treatment-related adverse events and associated costs.
Among the various prognostic parameters that could identify
high- and low-risk groups, advanced age, stage of the disease, the
EORTC prognostic scoring system, and association with multiple
endocrine neoplasia (MEN) 2B are commonly accepted as prog-
nostic factors (Byar et al., 1979; Tisell et al., 2003; Ito et al., 2005;
Fialkowski et al., 2008). Moreover, mutations in the RET onco-
gene are associated with lower survival rates (Elisei et al., 2008).
The Cdc25B phosphatase has also been shown as a new indica-
tor of aggressive MTC (Ito et al., 2005). Tumor aggressiveness
measured by Ki67 expression has been described as another prog-
nostic factor (Tisell et al., 2003). By monitoring serum Ct and
CEA concentration kinetics and calculating biomarker doubling-
times (DT), Barbet et al. (2005) demonstrated that Ct DT was an
independent predictor of survival, with a high predictive value, in
patients with measurable serum Ct, even after repeated surgery.
In this study, all 41 patients with Ct DT >2 years were still alive
at the end of the study, 2.9–29.5 years after initial surgery. Eight
patients (67%) with DT between 6 months and 2 years died of the
disease 40–189 months after surgery, and all 12 patients with Ct
DT <6 months died of the disease 6 months–13.3 years after ini-
tial surgery. Laure Giraudet et al. (2008) confirmed the prognostic
value of biomarker DT in a series of 55 consecutive patients.
IMMUNODETECTION WITH PRETARGETING
Before assessing the efficacy in a therapeutic application, pre-
targeting was evaluated using scintigraphic imaging with anti-
CEA× anti-DTPA-indium BsmAb and 111In-labeled bivalent
DTPA hapten in preclinical and clinical studies (Vuillez et al.,
1992; Peltier et al., 1993; Barbet et al., 1998; Hosono et al., 1998).
In preclinical MTC models, pretargeting using AES method has
demonstrated a more favorable therapeutic index than directly
labeled anti-CEA mAb (Hosono et al., 1998). In the first clinical
study performed in eight patients, immunoscintigraphy visual-
ized all known tumors and detected previously unknown tumor
sites (US and CT negative) in the neck and the liver (Peltier
et al., 1993). There were no false-positive results. Immunoscintig-
raphy was completed by radioimmunoguided surgery with the
help of a hand-held gamma probe. This technique allowed small
tumors not detected by the surgeon to be localized but failed to
detect two small lesions (1× 1 cm) corresponding to fibrosis with
infiltrated microscopic cancer. This first study was followed by
a larger study performed on 44 patients with elevated Ct serum
levels after resection of the primary MTC. Immunoscintigraphy
was performed 2, 5, and 24 h after hapten injection and, when
necessary, at longer time intervals. When available, a hand-held
gamma probe was used during surgery. Fifteen patients had known
tumor sites before immunoscintigraphy. Tumors were imaged in
12 (80%) of these patients, including three with liver metastases.
Five unknown tumor sites were detected. For the 29 patients with
occult disease, immunoscintigraphy detected high-activity uptake
sites in 21 patients (72%), including 5 in the liver. Twelve were
confirmed by surgery, one by guided morphologic imaging, and
one by venous catheterization. Radioimmunoguided surgery was
used on 14 patients. It was considered helpful by the surgeon in
12 patients, including 4 patients where it allowed the resection
of small, non-palpable nor visible, tumor-involved lymph nodes.
This short imaging study confirmed the advantage of pretargeting
and provided an incentive to proceed to go to the next step of RIT.
RIT IN METASTATIC MTC
A first phase I/II study was conducted in patients with metasta-
tic MTC with the F(ab’)2 fragment of the anti-CEA mAb MN-14
labeled with iodine-131 (Juweid et al., 1999). Fifteen patients were
enrolled in this study. Myelosuppression was the only significant
treatment-related dose-limiting toxicity. Human anti-mouse anti-
bodies (HAMA) developed in eight patients. Seven patients had
a median of 55% reduction of serum biomarkers. One patient
showed a dramatic improvement in the mass effect on the airways
caused by three tumor lesions in the neck, with a 45% reduc-
tion of overall tumor burden. The disease has continued to be
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radiologically stable in 11 of 12 assessable patients for periods
ranging from 3+ to 26+months.
A second phase I clinical study was performed using the same
radiolabeled mAb to determine the toxicity and therapeutic poten-
tial of high-dose 131I-MN-14 F(ab)2 combined with autologous
hematopoietic stem cell rescue in patients with rapidly progress-
ing metastatic MTC (Juweid et al., 2000). Twelve patients were
enrolled in this study. Starting doses were 900 cGy to the kid-
ney and no more than 1200 cGy to the lung and liver, with dose
increments of 300 cGy until the maximum tolerable dose is deter-
mined. Post-RAIT scintigraphies showed a tumor targeting in all
patients. Autologous hematopoietic stem cells were given to all
patients 1–2 weeks after therapy. Except for the instance of grade
3 gastrointestinal toxicity, non-hematologic toxicity was relatively
mild, with only grade 1 or 2 toxicity observed in nine patients. No
renal toxicity was seen. Of the 12 patients, 1 had partial remission
for 1 year, another had a minor response for 3 months, and 10 had
stabilization of disease lasting between 1 and 16 months.
A phase I/II clinical trial was started in 1996 to evaluate tox-
icity, pharmacokinetics, dosimetry, and anti-tumor activity of
pRAIT using murine anti-CEA× anti-DTPA BsMAb F6x734 and
a bivalent indium-DTPA hapten labeled with iodine-131, in 26
patients with metastatic MTC (Kraeber-Bodéré et al., 1999a). A
good tumor targeting was observed in the majority of patients,
with a high bone marrow uptake reflecting the high frequency
of bone marrow involvement confirmed by MRI (Mirallié et al.,
2005). Dose-limiting toxicity was hematological and maximum
tolerated activity was estimated at 1.8 GBq/m2 in the group of
patients with suspected bone marrow involvement. Some tumor
responses were observed, mainly in patients with a small tumor
burden and after repeated courses of pRAIT. Because of a relatively
high hematological toxicity and frequent immune responses, the
chimeric anti-CEA× anti-DTPA hMN14x734 BsMAb was devel-
oped. A prospective phase I optimization study was performed
in 34 patients with CEA-expressing tumors to determine optimal
BsMAb dose, hapten activity, and pretargeting interval (Kraeber-
Bodéré et al., 1999b, 2006). A BsMAb dose of 40 mg/m2 with a
pretargeting interval of 5 days appeared to be a good compro-
mise between toxicity and efficacy. HAMA elevation was observed
in 8% of patients and HAHA (human anti-human antibody) in
33%. Figure 1 shows the good tumor uptake observed in a patient
with a metastatic relapsing CEA-positive small cells lung cancer
after injection of a therapeutic activity of indium-DTPA hapten
labeled with iodine-131.
In 2006, Chatal et al. (2006) published a retrospective analy-
sis of survival of the series of MTC patients involved in the
two phase I/II pRIT clinical trials, comparing the survival of 29
patients given pRIT with that of 39 contemporaneous untreated
patients for whom data were collected by the French Endocrine
Tumor Group (GTE). A second objective was to examine whether
post-pRIT variations of Ct DT could be used as a surrogate
marker for survival by comparing, among treated patients, the
survival of biological responders and non-responders, defining
a responder as showing at least a 100% increase in Ct DT. The
patients were stratified in risk-groups according to Ct DT, and
patients with Ct DT<2 years were considered as high-risk patients.
This study showed that overall survival (OS) was significantly
FIGURE 1 | Immunoscintigraphies (posterior view) recorded in a
patient with a metastatic CEA-positive small cells lung cancer. This
patient was injected with the anti-CEA hMN14x734 bispecific antibody and
a therapeutic activity of 131I-di-DTPA-indium. The immunoscintigraphies
recorded 3, 6, and 8 days after hapten injection showed a good uptake in
lung (black arrow), mediastinum (white arrow), and brain (white arrowhead)
metastases.
longer in high-risk treated patients than in high-risk untreated
patients (median OS, 110 versus 61 months; P < 0.030). Treated
patients with bone/bone marrow disease had a longer survival
than patients without such involvement (10-year OS of 83 versus
14%; P < 0.023). Toxicity was mainly hematological and related to
bone marrow involvement. Patients with grade 4 thrombocytope-
nia received platelet infusions and those with grade 4 leucopenia
received G-CSF injections. No kidney toxicity was observed after
pRIT.
Following the encouraging results obtained in the two phase
I/II studies, a prospective phase II multicenter pRIT trial was
undertaken in progressive MTC patients with Ct DT shorter
than 5 years. From 2004 to 2008, 42 MTC patients were treated
with 40 mg/m2 of hMN-14xm734 and 1.8 GBq/m2 131I-di-DTPA-
indium bivalent hapten 4–6 days later (Salaun et al., 2012). Patients
were stratified in risk-groups according minimal DT (lowest
value between Ct- and CEA-DT) as follows: high-risk patients
with minimal DT lower than 6 months, intermediate-risk with
DT between 6 months and 2 years, and low-risk with DT longer
than 2 years. Disease control according RECIST criteria (objec-
tive response+ stabilization) was observed in 32 patients (76.2%),
including a durable complete response of at least 40 months
in 1 patient (2.4%) and durable stable disease (≥6 months)
in 31 patients (73.8%). Tumor uptake assessed by post-pRIT
immunoscintigraphy was a significant predictor of response.
Figure 2 shows the good tumor uptake in a metastatic MTC
patient. Subacute toxicity was mainly hematological, requiring
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FIGURE 2 | Immunoscintigraphy (anterior and posterior views)
recorded in a patient with metastatic medullary thyroid carcinoma.
This patient was injected with the anti-CEA hMN14x734 bispecific antibody
and a therapeutic activity of 131I-di-DTPA-indium. The immunoscintigraphy
recorded 4 days after hapten injection showed a good tumor uptake in liver
(black arrow), bone (white arrow), and brain (white arrowhead) metastases.
careful post-RAIT blood monitoring. Pre-RAIT biomarker DT
and impact on DT after pRIT were predictors of OS, confirm-
ing the value of serum biomarkers in selecting patients and
monitoring therapy.
Radioimmunotherapy could also be applied in a multimodality
strategy, especially in MTC patients with measurable metastatic
lesions. A synergistic effect was observed in MTC animal mod-
els using a combination of RAIT with paclitaxel (Kraeber-Bodéré
et al., 2002). Improvement of tumor response was also demon-
strated using a combination of RAIT with anti-angiogenic agents
such as thalidomide, CBOP11 (cyclopeptidic vascular endothelial
growth inhibitor), or bevacizumab (Kraeber-Bodéré et al., 2010;
Salaun et al., 2010). Pretreatment with bevacizumab improved
RIT efficacy, with similar toxicity as compared to RIT alone. Pre-
treatment by CBOP11 or thalidomide sensitized larger tumors
(>300 mm3), with increased leukopenia but not thrombocytope-
nia. An increase of the anti-tumor effect observed using the anti-
angiogenic drug combined with RIT was correlated with a decrease
of blood vessels shown by von Willebrand immunostaining. These
combinations could be assessed in clinical trials in MTC patients
with progressive and measurable tumor masses.
FUTURE DEVELOPMENTS OF PRETARGETED RIT
METHOD BASED ON BISPECIFIC ANTIBODY-HAPTEN BINDING
The two radionuclides usually used for RIT are yttrium-90
and lutetium-177 with a DOTA (1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid) chelating agent used for a stable binding.
This chelating agent is not adapted to anti-DTPA(In) antibody
which has been used up to now. Indeed, to ensure a high affinity
binding to this antibody it is necessary to load DTPA with indium
and then to load DOTA for a good stability binding with yttrium-
90 or lutetium-177. Consequently it was necessary to develop
another hapten-binding system. An anti-hapten antibody directed
to a derivative of histamine-succinyl-glycine (HSG) with a high
affinity was produced. Subsequently, a di-HSG-peptide was pre-
pared containing a single DOTA and allowed accommodation of a
number of radionuclides for imaging and therapeutic applications
including 68Ga, 124I, 18F, 90Y, and 177Lu (Sharkey et al., 2010).
Concerning the optimal type of construct including the anti-
CEA and anti-HSG antibodies it appeared that the trivalent form
with two valencies for CEA and one for HSG had the highest tar-
geting sensitivity. However, such an agent could not be efficiently
produced with acceptable yields. That problem led to the design
and development of an innovative and sophisticated system called
Dock and Lock (Rossi et al., 2006). Finally, a trivalent bispecific
structure referred to as TF2 and prepared using this Dock and
Lock method was composed of three stably linked Fab fragments
directed to CEA and a HSG peptide. The HSG peptide allows
facile and stable labeling with different radiometals, such as 177Lu
or 90Y, having favorable physical features that could improve pRIT
efficacy (Goldenberg et al., 2008; Schoffelen et al., 2010a).
Pretargeting utilizes separate administrations of these two
agents, and introduces new complexities concerning administra-
tion (molar doses of the agents, time interval between injections
and bispecific antibody to peptide ratios) in order to optimize the
treatment protocol. TF2 rapidly decreases in blood to less than
0.1% ID/g 24 h following injection. With a standard interval time
of 24 h between the two agents, rapid tumor uptakes of 15.5%
ID/g have been reported 1 h following the injection of the radiola-
beled peptide in a hepatic metastases model of colonic carcinoma
in mice, slowly decreasing to 4.6% ID/g at 48 h. In contrast, nor-
mal tissue uptakes were particularly low with maximal uptakes of
0.73% DI/g in blood and 2.38% ID/g in the kidneys leading to high
tumor to non-tumor ratios, especially in the blood, as compared
to direct RIT. Dosimetry and toxicity may be planned from mod-
els and pharmacokinetics, and the HSG peptide allows labeling
with different radionuclides. As expected, due to the rapid clear-
ance of the peptide, short-lived 211At was predicted to deliver the
highest absorbed dose to the tumors, kidney being dose limiting.
Other nuclides such as 90Y and 213Bi would also deliver highly
absorbed doses to the tumors with acceptable absorbed dose to
the kidneys. Beta emitters such as 90Y could be effective against
larger tumors with an estimated absorbed dose of 4.2 Gy for sub-
cutaneous tumors of 6 mm, with a favorable kidney dosimetry.
A major point is that no significant toxicity to the bone marrow
should be expected owing to the low activity in blood. (Frampas
et al., 2011a,b).
Some clinical trials are ongoing using the trivalent bispecific
anti-CEA and anti-HSG antibody TF2 and the 177Lu-DOTA-di-
HSG-peptide IMP-288 in patients with colorectal cancer and small
cell lung cancer.
The new generation AES products have a rapid distribution,
suggesting benefit of labeling with short half-live PET emitters
such as 68Ga or 18F, to develop a highly sensitive and specific
immuno-PET method in CEA-expressing tumors. Immuno-PET
and RIT could be applied in the context of a theranostic strategy
(McBride et al., 2006, 2009; Karacay et al., 2011). Schoffelen et al.
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(2010b) developed procedures for radiolabeling a small hapten-
peptide (1451 Da) with 68Ga or 18F to compare their specificity
with 18F-FDG for detecting tumors using a pretargeting proce-
dure in animal models of CEA-positive-human colonic tumor and
a CEA-negative tumor, or a local inflammation. The intravenous
injection in mice of anti-CEA× anti-hapten BsMAb was followed
16 h later by the injection of 5 MBq of 68Ga- or 18F-labeled hap-
ten peptides. Within 1 h, the CEA-positive tumor showed high
and specific targeting of 68Ga-IMP-288 (10.7± 3.6% ID/g tumor
uptake) and very low uptake in normal tissues (tumor-to-blood
ratio of 69.9± 32.3), compared to the CEA-negative tumor and
inflamed muscle (lower than 1.0% ID/g). Results were similar with
18F-labeled IMP-449. Contrary, 18F-FDG lacked in specificity as it
localized efficiently to the tumor but also in the inflamed muscle
(7.42± 0.20 and 4.07± 1.13% ID/g, respectively) and in several
normal tissues. Pretargeted Immuno-PET appears as a highly sen-
sitive and specific imaging method, well fitted with short-lived
radionuclides, more specific than 18F-FDG-PET. Two immuno-
PET clinical studies using new generation AES reagents and 68Ga
started in 2012 in France, with the aim to demonstrate the feasi-
bility of the method in CEA-positive MTC and breast carcinoma
patients and to optimize the pretargeting parameters.
METHOD BASED ON DNA-COMPLEMENTARY DNA BINDING
To improve the therapeutic index using the morpholino phospho-
rodiamidate oligomer (MORF)/complement MORF (cMORF)
pretargeting system the CC49 antibody directed to TAG-72 tumor
antigen has been conjugated with both biotin and MORF in
tumor-bearing mice (Liu et al., 2010). This directly labeled anti-
body has been extensively tested in preclinical and clinical stud-
ies. One day later avidin was injected and led to a decrease of
radioactive concentration in blood but not in the tumor result-
ing in a highly improved therapeutic index. This result should be
confirmed in clinical studies.
CONCLUSION
There is no doubt that some advantages of pretargeted RIT have
been clearly documented both in preclinical and clinical stud-
ies with regards to directly radiolabeled antibodies. This allows a
significant increase in the tumor-to-normal tissue ratios, especially
tumor-to-blood ratios, and subsequently allows a higher radioac-
tivity level to be injected without impairing hematologic toxicity.
Survival benefit has been shown using the two main pretargeting
models. With the three-step pretargeting using biotinylated anti-
tenascin antibody,avidin/streptavidin and 90Y-biotin,encouraging
results have been obtained in patients with high-grade glioma
(Paganelli et al., 2001). With the bispecific antibody-hapten pretar-
geting model a survival gain has also been documented in patients
with rapidly progressing metastatic MTC (Chatal et al., 2006).
Interestingly there were few objective responses but a long-term
stabilization up to more than 10 years was observed in patients
who progressed rapidly before RIT.
We can wonder what would be the best clinical indication for
pretargeted RIT. Conventional RIT with directly labeled antibodies
has proved to be efficient in the setting of disseminated micro-
scopic disease with substantial gain in survival (Liersch et al.,
2005, 2007; Morschhauser et al., 2008). In this situation of micro-
scopic clusters of malignant cells located in bone marrow and thus
rapidly accessible to intravenously injected antibody the potential
interest of pretargeting is not obvious. Otherwise large tumors,
more than 3–4 cm in diameter, are badly vascularized with necrotic
regions which can prevent both directly labeled antibodies or unla-
beled immunoconjugate from reaching and binding to tumor cells.
Consequently the most appropriate situation could be intermedi-
ate tumor sizes in the range of 1–3 cm in diameter where tumor
necrosis is still limited. In this situation the distribution of anti-
bodies (labeled and unlabeled) could be roughly homogenous 2 or
3 days after injection and the pretargeting technique would allow
injecting a higher activity level without impairing hematologi-
cal toxicity. The ongoing clinical trials with the Dock and Lock
technique are awaited before ascertaining the real future role of
pretargeted immuno-Pet and RIT.
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